Synopsis of recent research by authors named "David Willner"
- David Willner's research primarily focuses on the development of targeted drug delivery systems, particularly through the use of monoclonal antibody conjugates and dipeptide linkers to enhance the efficacy of doxorubicin in cancer treatment
- His studies demonstrate that employing branched peptide linkers and lysosomally cleavable dipeptides facilitates the specific release of doxorubicin within tumor cells, minimizing aggregation and improving therapeutic outcomes
- Willner's findings indicate that multiple enzymatic pathways may be involved in the release of doxorubicin from immunoconjugates, highlighting the potential for optimizing drug delivery mechanisms through careful selection of linkers and enzymatic considerations
